KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Change in Receivables (2021 - 2024)

Vir Biotechnology (VIR) has disclosed Change in Receivables for 4 consecutive years, with $8.7 million as the latest value for Q4 2024.

  • Quarterly Change in Receivables rose 142.57% to $8.7 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Dec 2024, up 1052.74% year-over-year, with the annual reading at $6.5 million for FY2024, 1052.74% up from the prior year.
  • Change in Receivables hit $8.7 million in Q4 2024 for Vir Biotechnology, up from $54000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $680.1 million in Q4 2021 to a low of -$883.8 million in Q2 2022.
  • Historically, Change in Receivables has averaged $778384.6 across 4 years, with a median of $54000.0 in 2024.
  • Biggest YoY gain for Change in Receivables was 142.57% in 2024; the steepest drop was 183.65% in 2024.
  • Year by year, Change in Receivables stood at $680.1 million in 2021, then crashed by 140.9% to -$278.2 million in 2022, then skyrocketed by 101.3% to $3.6 million in 2023, then surged by 142.57% to $8.7 million in 2024.
  • Business Quant data shows Change in Receivables for VIR at $8.7 million in Q4 2024, $54000.0 in Q3 2024, and -$2.7 million in Q2 2024.